Afatinib for the treatment of locally advanced or metastatic non-small cell lung cancer after previous platinum containing chemotherapy and gefitinib or erlotinib
 
Status Suspended
Process STA
Referral date 01 July 2010
Topic area
  • Cancer
  • Respiratory
Description

Scoped within Batch 12

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Communications manager: TBC
Executive Lead: TBC
Project manager: Jeremy Powell
Technical Lead: TBC

Timeline

Key events during the development of the guidance:

Date Update
28 July 2011

As you will be aware, the Department of Health has asked the Institute to conduct an appraisal of afatinib within its licensed indication for the treatment of locally advanced or metastatic non-small cell lung cancer after previous platinum containing chemotherapy and gefitinib or erlotinib as part of our 22nd wave work programme.

The Institute has been informed by the manufacturer that it is not expecting to receive a separate marketing authorisation for this indication. NICE has therefore decided to suspend this appraisal on its current work programme for the time being.

This indication is now planned to be part of the regulatory submission of afatinib for NSCLC, locally advanced and/or metastatic with EGFR mutation positive.

3 December 2010

Following on from information received from the manufacturer, dates for this appraisal will be confirmed once regulatory approval timelines are established.


For further information on how we develop guidance, please see our page about NICE technology appraisal guidance